ZTSHealthcare · Drug Manufacturers - Specialty & GenericThe 16 Wall Street analysts covering Zoetis, Inc. hold a median 12-month price target of $85 — +8.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 27 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Zoetis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Momentum (11): The shares have been drifting down relative to others.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ZTS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +8.7% from it.
Of the 20 most recent actions, 1 moved their price target up and 9 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | UBS | Maintains | Neutral | $80 → $85 |
| 20 Oct 2026 | Jefferies | Downgrade | Hold | $103 → $83 |
| 16 Oct 2026 | Goldman Sachs | Initiates | Neutral | $74 |
| 25 Aug 2026 | TD Cowen | Maintains | Buy | $104 → $94 |
| 25 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 20 Aug 2026 | Stifel | Maintains | Hold | $85 → $80 |
| 20 Aug 2026 | Stifel | Maintains | Hold | — |
| 11 Aug 2026 | BNP Paribas | Maintains | Outperform | — |
| 11 Aug 2026 | BNP Paribas | Maintains | Outperform | $146 → $110 |
| 11 Aug 2026 | Citigroup | Maintains | Buy | — |
| 11 Aug 2026 | Citigroup | Maintains | Buy | $112 → $96 |
| 10 Aug 2026 | Piper Sandler | Maintains | Neutral | $90 → $80 |
| 10 Aug 2026 | Piper Sandler | Maintains | Neutral | — |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $130 → $115 |
| 7 Aug 2026 | UBS | Maintains | Neutral | — |
| 7 Aug 2026 | UBS | Maintains | Neutral | $85 → $80 |
| 6 Aug 2026 | William Blair | Downgrade | Market Perform | — |
| 6 Aug 2026 | William Blair | Downgrade | Market Perform | — |
| 27 July 2026 | UBS | Maintains | Neutral | $99 → $85 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ZTS appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Zoetis, Inc. returned −46.0% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 50% of US stocks
Cheaper than 35% of US stocks
Cheaper than 8% of US stocks
Cheaper than 38% of US stocks
Higher than 28% of US stocks
Higher than 31% of US stocks
Higher than 85% of US stocks
Higher than 92% of US stocks
Higher than 87% of US stocks
Higher than 94% of US stocks
Higher than 97% of US stocks
Higher than 84% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Zoetis, Inc. has a market value of $32.3B and an enterprise value of $39.9B.
Revenue in the twelve months to 30 June 2026: $9.5B. The latest quarter shrank 0.2% year on year.
Net income over the same four quarters: $2.6B, a 27.5% net margin.
Diluted earnings per share, trailing twelve months: $6.07.
Free cash flow in the twelve months to 30 June 2026: $2.3B, after $524.0M of capital spending.
Zoetis, Inc. spent $3.6B on share buybacks and $889.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 12.9×; forward P/E: 12.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.71%, paying out 34% of earnings.
Zoetis, Inc. employs 14,500 people — $656K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Zoetis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zoetis (ZTS) closed at $81.03 in the latest trading session, down 1.18% from the previous day. The headline states that the decline was larger than the market’s.
Why it matters — ZTS watchers may note the stock’s daily decline and its performance relative to the market.
The article compares Zoetis with ImmuCell, describing Zoetis as offering diversification and stability, while ImmuCell has stronger sales growth and expansion potential.
Why it matters — The comparison highlights how Zoetis’s stability contrasts with ImmuCell’s growth and expansion profile.
Zoetis announced FDA approval for Convenia RTU for Dogs, an injectable suspension that provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections.
Why it matters — The approval adds a Zoetis treatment option intended to help more medium and large dogs access single-injection treatment.
Zoetis announced that Iris Knobloch will join its Board of Directors effective December 1, 2026. The company cited her global media and consumer business experience, public company board service, and consumer and digital expertise.
Why it matters — ZTS watchers may note the appointment as a change to the company’s board and the experience Knobloch brings.
Seeking Alpha’s October 2026 monthly screen ranks dividend-growth stocks with Dividend Safety scores of at least 8.0, forward yields of at least 2.5%, and prices at or below fair value. Its equally weighted top 10 portfolio yields 2.8% and underperformed SPY over the past five years.
Why it matters — The item concerns dividend-growth screening criteria and portfolio performance, which may be relevant to readers assessing ZTS in that context; the excerpt does not say whether ZTS is included.
The 16 Wall Street analysts covering Zoetis, Inc. have a median 12-month price target of $85, with estimates ranging from $74 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Zoetis, Inc., 5 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zoetis, Inc. 48 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Zoetis, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +8.7% from the last close, and Ticker Nerd's factor model ranks Zoetis, Inc. 48 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Zoetis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $74 to $115 over the next 12 months.
Zoetis, Inc. returned -46.0% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Zoetis Inc. Class A Common Stock represents Zoetis, a global animal health company focused on medicines, vaccines, diagnostics, and related technologies for pets and livestock.
The most recent item we track (Zacks Investment Research, 23 Oct 2026): "Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note". Zoetis (ZTS) closed at $81.03 in the latest trading session, down 1.18% from the previous day. The headline states that the decline was larger than the market’s.
Zoetis Inc. Class A Common Stock represents Zoetis, a global animal health company focused on medicines, vaccines, diagnostics, and related technologies for pets and livestock. Zoetis develops and markets products used by veterinarians, livestock producers, and pet owners across companion animals such as dogs, cats, and horses, as well as livestock including cattle, swine, poultry, fish, and sheep. Its portfolio includes parasiticides, dermatology treatments, pain and sedation products, anti-infectives, diagnostic tools, genetic tests, and precision animal health solutions. The company also provides reference laboratory services, rapid tests, instruments, and other non-pharmaceutical offerings that support disease detection and animal care. Headquartered in Parsippany, New Jersey, Zoetis operates in the United States and international markets, serving a broad range of animal health needs across clinical, agricultural, and diagnostic settings.
CEO Ms. Kristin C. Peck · 14,500 employees · United States · https://www.zoetis.com
